ReviewPathogens (Basel, Switzerland)2019
The Role of
Review in Pathogens (Basel, Switzerland), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 117 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
117 citing papers in PubMed, 192 citations in OpenAlex.
- Emerging XDR and MDR Pseudomonas aeruginosa strains from Oreochromis niloticus reveal high pathogenicity, virulence determinants, antimicrobial resistance genes, and oprL sequence diversity.Scientific reports · 2026Article
- Article
- Intracellular barriers and receptor masking limit success of abioRxiv : the preprint server for biology · 2026Article
- Article
- The Occurrence of Bacterial Infections in Equine Wounds and Abscesses in Horses from 2019 to 2023.Veterinary sciences · 2026Article
- Synergistic Bactericidal Effects of R- and F-Type Pyocin Cocktails Against ClinicalAntibiotics (Basel, Switzerland) · 2026Article
- Essential Oils and Their Multifunctional Activities Against Pseudomonas aeruginosa: Current Evidence and Perspectives.MicrobiologyOpen · 2026Review
- Role of cell-associated and secretion-independent virulence factors of Pseudomonas aeruginosa in microbial keratitis and anti-virulence therapeutic strategies.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026Review
- The neuropeptide neuromedin U receptor NMUR-1 buffers insulin receptor signaling in bacteria-dependent C. elegans survival.PLoS genetics · 2026Article
- Pathogen-Specific Regulation of Renin-Angiotensin System Genes in Epithelial Cells: A Comparative Study of SARS-CoV-2 Spike Protein N-Terminal Domain Fragment and Bacterial Lipopolysaccharide.Pathogens (Basel, Switzerland) · 2026Article
- Molecular basis for inhibition of α-thrombin activity by bacterial lipopolysaccharides.Scientific reports · 2026Article
- Lipopolysaccharide-targeting treatments for multidrug-resistantExpert opinion on therapeutic targets · 2026Review
- Article
- Raman spectroscopy reveals growth phase-dependent molecular differences in bacterial membrane vesicles.Journal of bacteriology · 2026Article
- Steering the course: targeting and exploiting surface receptors in phage therapy.Journal of bacteriology · 2026Review
- Virulent strains of Pseudomonas aeruginosa are more disruptive during invasion of a microbial model community.FEMS microbiology letters · 2026Article
- Antibiotic resistance inFrontiers in microbiology · 2026Review
- Article
- Article
- Article
57 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
The major constituent of the outer membrane of Gram-negative bacteria is lipopolysaccharide (LPS), which is comprised of lipid A, core oligosaccharide, and O antigen, which is a long polysaccharide chain extending into the extracellular environment. Due to the localization of LPS, it is a key molecule on the bacterial cell wall that is recognized by the host to deploy an immune defence in order to neutralize invading pathogens. However, LPS also promotes bacterial survival in a host environment by protecting the bacteria from these threats. This review explores the relationship between the different LPS glycoforms of the opportunistic pathogen
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.